Gilead Sciences: Lymphoma, B-Cell trials

The registry lists 17 Lymphoma, B-Cell studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 13Phase 2 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell LymphomaTerminatedNCT04314843Phase 1Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedNCT04002401Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaCompletedNCT03761056Phase 2Results posted
• Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedNCT03704298Phase 1Results posted
• Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's LymphomaTerminatedNCT02953509Phase 1/2Results posted
• Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02926833Phase 1/2Results posted
• Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)TerminatedNCT02568683Phase 1/2Results posted
• Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedNCT02348216Phase 1/2Results posted
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
• Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasCompletedNCT01282424Phase 2Results posted
• Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic LeukemiaCompletedNCT01088048Phase 1Results posted
• A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous TreatmentActive, not recruitingNCT06539338Phase 1
• Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
• Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingNCT03153462
• Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT02625480Phase 1/2
• Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedNCT00546793Phase 1/2
• Treatment of Non-Hodgkin's Lymphoma With 90Y-hLL2 IgGCompletedNCT00061425Phase 1/2